Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas.
about
Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical DilemmasOverexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.Distribution of estrogen and progesterone receptors isoforms in endometrial cancer.Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage.Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression.Function and regulation of MTA1 and MTA3 in malignancies of the female reproductive system.Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.Immunosuppressive Glycodelin A is an independent marker for poor prognosis in endometrial cancer.Progesterone action in breast, uterine, and ovarian cancers.HNRNP G and HTRA2-BETA1 regulate estrogen receptor alpha expression with potential impact on endometrial cancer.Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.p21-Activated Kinases 1, 2 and 4 in Endometrial Cancers: Effects on Clinical Outcomes and Cell Proliferation.Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.Dietary vitamin D exposure prevents obesity-induced increase in endometrial cancer in Pten+/- miceComparative effects of er-xian decoction, epimedium herbs, and icariin with estrogen on bone and reproductive tissue in ovariectomized rats.Estrogen receptors and human disease: an update.Androgen receptors are acquired by healthy postmenopausal endometrial epithelium and their subsequent loss in endometrial cancer is associated with poor survivalMultiple direct and indirect mechanisms drive estrogen-induced tumor growth in high grade serous ovarian cancers.A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group studyInfluence of VEGFR and LHCGR on endometrial adenocarcinomaEpidemiology of Endometrial Carcinoma: Etiologic Importance of Hormonal and Metabolic Influences.Evaluation of the Pathogenesis of Tumor Development from Endometriosis by Estrogen Receptor, P53 and Bcl-2 Immunohistochemical StainingTraditional Approaches to Molecular Genetic Analysis.Molecular markers and clinical behavior of uterine carcinosarcomas: focus on the epithelial tumor component.Coexistence of adenomyosis uteri and endometrial cancer is associated with an improved prognosis compared with endometrial cancer only.Prostaglandin receptor EP3 regulates cell proliferation and migration with impact on survival of endometrial cancer patients.Hormone Receptor Expression in Spontaneous Uterine Adenocarcinoma in Fischer 344 Rats.Inhibin-βA subunit immunolabeling as a prognostic factor in endometrioid adenocarcinomas: a matter of evaluation?E-cadherin as a prognostic marker in human serous carcinomas of the ovary: an immunohistochemical analysis.
P2860
Q21261320-4EBD75D1-07BB-468C-93D0-8471855993BAQ28074769-0E2BC66A-8166-4918-B14C-DA1A592F5990Q33599430-07F247FD-C660-4E17-9582-EA8D7F062A5BQ33616773-20E59E6D-0418-48F8-9B33-818AE48925B7Q34212950-507127EF-F7F0-4C8D-AAE8-4CBE09D69BA9Q34312829-EA4AB278-DB76-4CEA-B619-8D0004AC938DQ34443694-F805DF87-027E-4723-824D-0DAD905B3CE4Q34486859-A208ABCB-62D8-48F8-A848-9303330082ACQ35078816-726085AE-7EE2-48F6-BF56-7225E0A6FF39Q35108906-29A4F933-B064-4EBB-A26A-7282E8F41F8CQ35164945-66F13B3C-06E0-45A3-965B-7EE9B65FB7FFQ35623021-9B2EB3FD-5718-4EEC-83CA-F9016D60C6D0Q35720268-EEE073B3-780C-4241-B460-6D931DA16B16Q35879733-1C25CA7D-37BA-411E-8201-6E6F02121EFFQ36062947-1919C60B-0147-4BF3-A6A3-94CCA2286F9EQ36438909-8375C755-555E-4B19-B84B-2F811E2FEEB7Q36661810-305A4950-68CD-41F2-8313-F6E91A018006Q36707726-F3EF4364-9FA8-47C8-8A39-E96F5767CEC2Q36946741-E42968F5-888B-494C-8B28-946E23EA2F8FQ36980484-488CEA31-ECEE-4C74-A2DA-2CDE3AD11936Q37205959-9B9298D6-46A8-4E8E-9CB6-777A597696D8Q38788210-AB20D7BA-00CA-410A-AB9D-1152D2150E4EQ38997188-04971EAC-1056-46A0-A056-228BEBA840A7Q39026764-2B20EAA3-F8AA-4E33-AEDD-23B113A5A61AQ39750078-B21FDF62-CC7B-4F2A-B758-AB21794D72C9Q41618692-61293893-ACA2-4E1C-866C-A70F2D6A5314Q50128233-73A7CA73-4016-4C66-8ADA-999C724206CDQ53208025-D4451087-38FC-42C4-85A1-E68553CA0B40Q53295028-C698220F-9AFF-4AB4-936F-A6246E20F27CQ54676964-FA700722-8B0E-4FD4-91FF-FA076CDE1758
P2860
Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@en
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@nl
type
label
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@en
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@nl
prefLabel
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@en
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@nl
P2093
P1476
Prognostic significance of oes ...... -B) in endometrial carcinomas.
@en
P2093
Andrea Gingelmaier
Christian Schindlbeck
Christina Kuhn
Darius Dian
Doris Mayr
Franz Willgeroth
Harald Sommer
Ioannis Mylonas
Klaus Friese
Naim Shabani
P304
P356
10.1016/J.EJCA.2007.08.014
P577
2007-11-01T00:00:00Z